


ISSN: 2637-7748



# A Treatable Leukodystrophy Presenting as Familial Spastic Paraparesis with Homozygous Variation in MTHFR Gene- A Case Report

**Aswin G<sup>1</sup>, Philo Hazeena P<sup>2\*</sup>, Javed Ahmed<sup>3</sup> and Shankar V<sup>4</sup>**<sup>1</sup>Senior resident Neurology, India<sup>2</sup>Neurology, India<sup>3</sup>Consultant neurologist, India<sup>4</sup>Professor and Head Neurology, India

## Abstract

The MTHFR enzyme deficiency is an autosomal-recessive inborn error of folate metabolism. The Clinical presentation can vary from asymptomatic to severe neurological manifestations with pyramidal, cerebellar signs, dementia, and epileptic seizures. We report a 23-year-old male with familial gradually progressive spastic paraparesis with seizures and poor scholastic performance. Patient was diagnosed with MTHFR enzyme deficiency presenting as leukodystrophy with spastic paraparesis, which is treatable on early diagnosis.

**Keywords:** Methylene tetrahydrofolate reductase; Spastic paraparesis; Leukoencephalopathy

**\*Corresponding author:** Philo Hazeena,  
Senior resident Neurology, India

**Submission:** August 02, 2021

**Published:** September 29, 2021

Volume 4 - Issue 4

**How to cite this article:** Aswin G, Philo Hazeena P, Javed Ahmed, Shankar V. A Treatable Leukodystrophy Presenting as Familial Spastic Paraparesis with Homozygous Variation in MTHFR Gene- A Case Report. Tech Neurosurg Neurol. 4(4). TNN. 000591. 2021. DOI: [10.31031/TNN.2021.04.000591](https://doi.org/10.31031/TNN.2021.04.000591)

**Copyright@** Philo Hazeena P, This article is distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.

## Introduction


Methylenetetrahydrofolate reductase (MTHFR) is a cytoplasmic enzyme that catalyses' the reduction of 5,10- methylenetetrahydrofolate to 5-methyl tetrahydrofolate. Mutations in MTHFR gene lead to hyperhomocysteinemia and homocystinuria due to abnormalities in the remethylation of homocysteine to methionine. Even mild hyperhomocysteinemia represents an important risk factor for atherosclerosis and vascular disease, including stroke, and it also contributes to the development of cognitive impairment [1]. Patients may present with a wide spectrum of clinical features, including cognitive and neuropsychiatric changes, movement disorders, spasticity and seizures. Hereditary spastic paraparesia is described as a genetic, heterogeneous disorder leading to axonal degeneration of the spinal pathways and mostly classified in either pure or complex [2]. The MTHFR enzyme deficiency is an autosomal-recessive inborn error of folate metabolism. Clinical manifestations can vary from asymptomatic to severe neurological manifestations with pyramidal, cerebellar signs, dementia, and epileptic seizures. Hereby, we report a 23-year-old male with familial gradually progressive spastic paraparesis with seizures and poor scholastic performance. Patient was diagnosed with a type of leukodystrophy, which is treatable on early diagnosis.

## Case Report

A 23-year-old male patient born out of 3rd degree consanguineous parentage with normal perinatal history, presented to us with unsteadiness while walking and stiffness of both lower limbs. The symptoms had worsened after a fall. Patient had difficulty to grip slippers for the past 3 years, which was gradual in onset and slowly progressing to an extent that he has

changed his slippers to one with a strap. Past two years patient noticed that he was tripping over small objects due to the stiffness and has difficulty in wearing his pants while standing, as he would lose balance. For the past one year he also noticed difficulty in going up and down the stairs with tightness of legs. He had poor scholastic performance since 8th standard. He had an episode of tonic clonic movements of both upper limbs and lower limbs with tongue bite 1 ½ years back and is being treated with Tablet Leviteracetam. He was able to perceive the sensations normally in the lower limbs. There was no worsening of symptoms in the dark. He didn't have any cranial nerve and bladder involvement. There was a significant family history with his younger brother having similar complaints of spastic paraparesis. He complained of headache 6-8 episodes per month lasting more than 6 hours, throbbing type, associated with photophobia and phonophobia. Clinical examination revealed normal cognitive assessment with no cranial nerve deficits. Motor system evaluation revealed hypertonia of both lower limbs, reflexes were brisk in both lower limbs with bilateral extensor plantar response and a spastic gait. His investigations showed

a normal hemogram, renal, liver and thyroid function tests. His vitamin B12 levels were found to be low (123pg/ml). On evaluating further for low vitamin B12 levels, his serum homocysteine levels were found to be high. Serum Homocysteine levels were (>50). Neuroimaging showed a patchy T2 hyperintensities involving the bilateral occipital periventricular white matter with confluent T2 hyperintensities involving the bilateral centrum semiovale and high frontal deep white matter (Figure 1). MRI spine and nerve conduction study of all four limbs was normal. In view of a significant family history with features of spastic paraparesis along with MRI showing white matter changes, we evaluated him further for the hereditary causes of spastic paraparesis. The genetic panel for leukodystrophy and hereditary spastic paraplegia was sent, which showed a homozygous missense variation in the exon 2 of MTHFR gene (c.459C>G) (p.lle153Met) .Patient was diagnosed to have methylene tetrahydrofolate reductase deficiency. Patient was treated with vitamin B12 (1.5mg/day), folic acid (15mg/day), and vitamin B6 (30mg/day) and on initial follow up, patient showed improvement in his gait.



**Figure 1:** MRI brain.

## Discussion

The MTHFR enzyme deficiency is an autosomal-recessive inborn error of folate metabolism. Clinical manifestations can vary from asymptomatic to severe neurological manifestations with pyramidal, cerebellar signs, dementia, and epileptic seizures. The symptoms can manifest over a wide range of age from neonates to the adulthood. Infants presents with seizures, hypotonia, apnoea, microcephaly, progressing to coma, and death if untreated due to severely reduced residual enzyme activity [3]. Developmental delay, seizures including progressive myoclonic epilepsy, psychiatric disturbances, spastic gait, and ataxia occur in childhood and adolescent onset. In adult-onset enzyme deficiency, spastic paraparesis mimicking hereditary spastic paraparesis, psychotic episodes, cognitive disorder, stroke, peripheral neuropathy, and relapsing encephalopathy are the clinical manifestations [4].

Patients show moderate homocystinuria, hyperhomocysteinemia with low or low-normal methionine levels, radiologically, they show brain white matter changes (leukoencephalopathy). The leukoencephalopathy is usually periventricular, with a posterior predominance, and can involve U fibers. Our patient presented with gradually progressive spastic paraparesis with imaging features of leukoencephalopathy. Serum homocysteine was high with low vitamin B12 levels. Genetic testing showing a homozygous missense variation in the exon 2 of MTHFR gene (c.459C>G) (p.Ile153Met) [5]. He was diagnosed to have methylene tetrahydrofolate reductase deficiency Mahale R et al<sup>5</sup> in India observed similar kind of case report in child with rapidly progressive spastic paraparesis and behavioural disturbance of 3 month duration. Another case report by Gales et al. [6] of two adult siblings who experienced focal epilepsy at 18 years old as a first disease manifestation,

without other symptom during several years. Upon diagnosis, both patients received metabolic treatment comprising B9, B12 and betaine which has stopped the occurrence of seizures, allowing discontinuation of anti-epileptic drugs. Brain MRI showed a mostly periventricular white matter changes in 71% of cases. All patients stabilized or improved following metabolic treatment. Despite being rare, adolescence/adult onset MTHFR deficiency can nevertheless be successfully treated. Therefore, homocysteine levels should be tested in various unexplained neuro-psychiatric syndromes like epilepsy or spastic paraparesis, even if isolated, since waiting for completion of the clinical picture is likely to increase the risk of irreversible neurological damage.

Our patient's presentation was similar to the study by Lossos et al. [7] where both pairs of siblings presented with a similar combination of progressive spastic paraparesis and polyneuropathy, variably associated with behavioural changes, cognitive impairment, psychosis, seizures, and leukoencephalopathy, beginning between the ages of 29 and 50 years. The finding was in contrast to a study by Iida S et al. [8] where a 15-year-old boy with MTHFR deficiency who presented with a slowly progressive decline of school performance and a spastic gait. Rapidly deteriorating psychosis and repetitive seizures triggered by a febrile infection prompted neurological investigation. He had significantly elevated total plasma homocysteine and urinary homocystine levels, as well as a decreased plasma methionine level. Brain magnetic resonance imaging (MRI) revealed leukoencephalopathy. DNA gene sequencing showed c.446\_447 del GC ins TT and c.137G > A and c.665C > T heterozygous mutations in the MTHFR gene of the patient. Oral administration of betaine drastically improved his clinical symptoms within a few months. After 8 months of treatment, his total plasma homocysteine level moderately decreased; and the plasma methionine concentration became normalized. Timely molecular diagnosis and treatment with high dose of methyl donors is critical for the survival of these patients. Identification of the pathogenic variants of MTHFR gene may extend the knowledge about the spectrum of mutations and highlight the proper genotype-phenotype correlation.

## Conclusion

In adults presenting with familial gradually progressive spastic paraparesis, homocysteine levels should be evaluated. Generally, leukodystrophies are considered non treatable. Though, MTHFR deficiency is rare, it should be considered as an important differential while evaluating patients presenting with familial spastic paraparesis as it can be treated with early diagnosis.

## References

- Vieira D, Florindo C, Tavares De Almeida I, Macário MC (2020) Adult-onset methylenetetrahydrofolate reductase deficiency. *BMJ Case Rep* 13(3): 13-16.
- Beukelaer N, Bar On L, Hanssen B, Peeters N, Prinsen S, et al. (2021) Muscle characteristics in pediatric hereditary spastic paraplegia vs. bilateral spastic cerebral palsy: an exploratory study. *Front Neurol* 12: 1-10.
- Khan FMA, Dave D, Rohatgi S, Nirhale S, Rao P, Naphade P (2019) MTHFR mutation- A rare potentially treatable cause of adult-onset complicated hereditary spastic paraplegia. *J Neurol Sci* 405: 325.
- Lynch DS, Wade C, Paiva ARB De, John N, Kinsellaja, et al. (2019) Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era. *J Neurol Neurosurg Psychiatry* 90(5): 543-554.
- Mahale R, Gautam J, Arunachal G, Alappati S, Varghese N, et al. (2021) Rapidly progressive spastic paraparesis due to hyperhomocysteinemia in child with MTHFR gene mutation and mitochondrial Complex I deficiency: A rare association. *J Pediatr Neurosci*.
- Gales A, Masingue M, Millecamps S, Giraudier S, Grosliere L, et al. (2018) Adolescence/adult onset MTHFR deficiency may manifest as isolated and treatable distinct neuro-psychiatric syndromes. *Orphanet J Rare Dis* 13(1): 1-8.
- Lossos A, Teltsch O, Milman T, Meiner V, Rozen R, et al. (2014) Severe methylenetetrahydrofolate reductase deficiency: Clinical clues to a potentially treatable cause of adult-onset hereditary spastic paraparesia. *JAMA Neurol* 71(7): 901-904.
- Iida S, Nakamura M, Asayama S, Kunieda T, Kaneko S, et al. (2017) Rapidly progressive psychotic symptoms triggered by infection in a patient with methylenetetrahydrofolate reductase deficiency: A case report. *BMC Neurol* 17(1): 47.

For possible submissions Click below:

[Submit Article](#)